TREATMENT DECISION-MAKING IN INFLAMMATORY BOWEL DISEASES (IBD): A CANADIAN SURVEY AMONG PATIENTS AND PHYSICIANS IN THE CITE-IBD STUDY
Author(s)
Victor Kramer, PhD1, Chloe Langevin, MSc1, Laura Targownik, MD2, Frank Hoentjen, MD PhD3.
1Merck Canada Inc., Kirkland, QC, Canada, 2Division of Gastroenterology and Hepatology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada.
1Merck Canada Inc., Kirkland, QC, Canada, 2Division of Gastroenterology and Hepatology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada.
OBJECTIVES: Shared decision-making (SDM) is a collaborative approach to navigating complex treatment decisions between patients and physicians. This study examined SDM, the impact of inflammatory bowel disease (IBD) on productivity, and burden of fibrostenotic disease.
METHODS: A cross-sectional, online survey was conducted among patients and gastroenterologists across Canada, excluding Newfoundland & Labrador. Eligible patients were ≥18 years old with moderate-to-severe IBD and initiated/switched advanced IBD therapy. Eligible gastroenterologists actively treated patients with IBD. Instrument scores (SDM-Q-9, SDM-Q-DOC, and Work Productivity and Activity Impairment Questionnaire) were calculated according to guidelines and all data were analyzed descriptively.
RESULTS: The survey included 403 patients (196 Crohn’s disease [CD] and 207 ulcerative colitis [UC]) and 50 gastroenterologists. Patients with CD and UC were similar in mean age (39 and 38 years, respectively), gender (53% and 54% female), and time since diagnosis (62% and 77% with ≤3 years). Most patients used tumour necrosis factor inhibitors (CD: 60%, UC: 66%), followed by interleukin-12/23 inhibitors (CD: 18%, UC: 11%) to treat their IBD. Gastroenterologists were predominantly based in academic/research institutions (34%), with a mean of 17 years of experience treating IBD. The mean SDM-Q-9 raw score was 32/45 for CD and 31/45 for UC (indicating high perceived SDM). Among gastroenterologists, the mean SDM-Q-Doc score was 35/45. Among employed patients, the mean overall work impairment due to IBD was 35% and 36% for CD and UC, respectively, and the mean daily activity impairment was 32% for both. Gastroenterologists reported 40% of patients with fibrostenotic disease underwent surgery; 28% required endoscopic dilation.
CONCLUSIONS: Both patients and physicians placed high importance on SDM for advanced therapies, while patients reported meaningful impact of IBD on productivity and activity. Fibrostenotic disease was associated with significant surgical intervention. These results may help identify opportunities to enhance satisfaction with therapy through SDM to improve clinical and productivity outcomes.
METHODS: A cross-sectional, online survey was conducted among patients and gastroenterologists across Canada, excluding Newfoundland & Labrador. Eligible patients were ≥18 years old with moderate-to-severe IBD and initiated/switched advanced IBD therapy. Eligible gastroenterologists actively treated patients with IBD. Instrument scores (SDM-Q-9, SDM-Q-DOC, and Work Productivity and Activity Impairment Questionnaire) were calculated according to guidelines and all data were analyzed descriptively.
RESULTS: The survey included 403 patients (196 Crohn’s disease [CD] and 207 ulcerative colitis [UC]) and 50 gastroenterologists. Patients with CD and UC were similar in mean age (39 and 38 years, respectively), gender (53% and 54% female), and time since diagnosis (62% and 77% with ≤3 years). Most patients used tumour necrosis factor inhibitors (CD: 60%, UC: 66%), followed by interleukin-12/23 inhibitors (CD: 18%, UC: 11%) to treat their IBD. Gastroenterologists were predominantly based in academic/research institutions (34%), with a mean of 17 years of experience treating IBD. The mean SDM-Q-9 raw score was 32/45 for CD and 31/45 for UC (indicating high perceived SDM). Among gastroenterologists, the mean SDM-Q-Doc score was 35/45. Among employed patients, the mean overall work impairment due to IBD was 35% and 36% for CD and UC, respectively, and the mean daily activity impairment was 32% for both. Gastroenterologists reported 40% of patients with fibrostenotic disease underwent surgery; 28% required endoscopic dilation.
CONCLUSIONS: Both patients and physicians placed high importance on SDM for advanced therapies, while patients reported meaningful impact of IBD on productivity and activity. Fibrostenotic disease was associated with significant surgical intervention. These results may help identify opportunities to enhance satisfaction with therapy through SDM to improve clinical and productivity outcomes.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO10
Topic
Clinical Outcomes, Health Service Delivery & Process of Care, Patient-Centered Research
Topic Subcategory
Clinician Reported Outcomes
Disease
Gastrointestinal Disorders